Nexsphere-F Knee OA Data: Solid Safety, Undifferentiated Efficacy, Payer Case Unbuilt
NextBiomedical's Nexsphere-F, an artery-blocking device, demonstrated significant efficacy in a European prospective observational study for knee...
BOT+BAL Phase Ib OS Signal in MSS mCRC: Durable Plateau Compelling, Randomized Proof Absent
Agenus announced that its combination therapy of botensilimab (BOT) and balstilimab (BAL) demonstrated a median overall survival (OS) of 21.2 months and a...
Annamycin MIRACLE Part A Unblinding: Pivotal Signal or Premature Confidence in R/R AML?
Moleculin Biotech's CEO, Walter Klemp, participated in a Virtual Investor "What This Means" segment to discuss positive preliminary unblinded efficacy results...
Acoramidis Cardiorenal Posthoc Signal: Differentiation Claim Meets Payer Equivalence Verdict
BridgeBio's protein stabilizing therapy, Attruby, demonstrated significant kidney-protective benefits in patients with transthyretin amyloidosis cardiomyopathy...
MP0712 Enters SCLC Arena Against Approved DLL3 Rival: Mechanism Differentiates, But Evidence Vacuum Persists
Molecular Partners and Orano Med have announced the dosing of the first patient in their Phase I/IIa multi-centre US trial for MP0712. This novel radio-DARPin...
Brii's HBV Functional Cure Rates Impress, But Durability Void Remains the Decisive Risk
Brii Biosciences reported topline end-of-treatment (EOT) data from its Phase IIb ENRICH and ENHANCE trials, evaluating sequential and concurrent regimens of...
Clinical Trial Updates06 Jul 2026
NextBiomedical's Nexsphere-F, an artery-blocking device, demonstrated significant efficacy in a European prospective observational study for knee...
Clinical Trial Updates06 Jul 2026
Agenus announced that its combination therapy of botensilimab (BOT) and balstilimab (BAL) demonstrated a median overall survival (OS) of 21.2 months and a...
Clinical Trial Updates06 Jul 2026
Moleculin Biotech's CEO, Walter Klemp, participated in a Virtual Investor "What This Means" segment to discuss positive preliminary unblinded efficacy results...
Clinical Trial Updates06 Jul 2026
BridgeBio's protein stabilizing therapy, Attruby, demonstrated significant kidney-protective benefits in patients with transthyretin amyloidosis cardiomyopathy...
Clinical Trial Updates06 Jul 2026
Molecular Partners and Orano Med have announced the dosing of the first patient in their Phase I/IIa multi-centre US trial for MP0712. This novel radio-DARPin...
Clinical Trial Updates06 Jul 2026
Brii Biosciences reported topline end-of-treatment (EOT) data from its Phase IIb ENRICH and ENHANCE trials, evaluating sequential and concurrent regimens of...
Regulatory Approvals01 Jul 2026
Viridian Therapeutics received FDA approval for Lumvoa to treat thyroid eye disease, positioning it as a strong competitor to Amgen's Tepezza. Lumvoa offers a...
Regulatory Approvals01 Jul 2026
The New England Journal of Medicine has retracted a pivotal publication for Amgen's rare disease drug, Tavneos, following an ongoing FDA investigation into...
Regulatory Approvals01 Jul 2026
Unicycive Therapeutics received a second Complete Response Letter (CRL) from the FDA for its drug, oxylanthanum carbonate (OLC), intended for treating...
Regulatory Approvals01 Jul 2026
Imviva Biotech announced that the U.S. FDA granted Investigational Device Exemption (IDE) authorization for Adaptive Biotechnologies’ clonoSEQ® assay for use...
Regulatory Approvals01 Jul 2026
Praxis Precision Medicines' investigational epilepsy therapy, relutrigine, faces a three-month delay in its FDA target decision date. The agency classified...
Regulatory Approvals01 Jul 2026
The U.S. Food and Drug Administration (FDA) has approved Tregzi, a novel allogeneic T-cell-based immunotherapy, for improving chronic graft-versus-host disease...
Mergers and Acquisitions06 Jul 2026
Genentech has entered an exclusive global research and licensing agreement with Astex Pharmaceuticals, a U.K. biotech, to develop an investigational breast...
Mergers and Acquisitions01 Jul 2026
Investment firm Deerfield Management, through its portfolio company Boulevard Bio, has licensed MTS-128, a trispecific T cell engager for autoimmune disease,...
Mergers and Acquisitions01 Jul 2026
Beeline Medicines has secured an additional $126.3 million in its Series A funding round, bringing the total raised to $426.3 million. This substantial capital...
Mergers and Acquisitions01 Jul 2026
French pharmaceutical company Ipsen is set to acquire California-based Kartos Therapeutics in a deal valued at $450 million upfront, with potential goal-based...
Mergers and Acquisitions25 Jun 2026
Novartis and Antares Therapeutics have entered a collaboration to develop small molecule oncology therapies. Novartis will provide $105 million in upfront cash...
Mergers and Acquisitions25 Jun 2026
NurExone Biologic Inc.'s U.S. subsidiary, Exo-Top Inc., has entered a binding Memorandum of Understanding (MOU) with ExoLyra LLC for the exclusive distribution...
enterprise AI research platform06 Jul 2026
Learn what an enterprise AI research platform is, how it supports life sciences teams, and the key features to evaluate before choosing a solution.
AI expert intelligence06 Jul 2026
Learn how KnolPersona uses AI to simulate expert perspectives, helping life sciences teams evaluate evidence, identify gaps, and support stronger decisions.
traceable AI pharma06 Jul 2026
Learn what traceable AI is, the standards that support it, and why pharma organizations rely on it for transparent, compliant, and evidence-based decisions.
AI research platform04 Jul 2026
Compare KnolAI and ChatGPT for pharma use cases, including evidence management, traceability, governance, and support for regulated workflows.
enterprise knowledge retrieval04 Jul 2026
Compare KnolAI and Elicit to understand how they support research, evidence management, traceability, and compliance in regulated industries.
enterprise knowledge graph29 Jun 2026
Learn what an enterprise knowledge graph is, how it connects data across life sciences, and why it supports better search, insights, and decision-making.
Private by design. Speaks your language. Proven at scale
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
